(Q44361769)

2 December 2017

title

Herpes zoster guideline of the German Dermatology Society (DDG). (English)

1 reference

2 December 2017

1 reference

Gross G

1

1 reference

2 December 2017

Schöfer H

2

1 reference

2 December 2017

Wassilew S

3

1 reference

2 December 2017

Friese K

4

1 reference

2 December 2017

Timm A

5

1 reference

2 December 2017

Guthoff R

6

1 reference

2 December 2017

Pau HW

7

1 reference

2 December 2017

Malin JP

8

1 reference

2 December 2017

Wutzler P

9

1 reference

2 December 2017

Doerr HW

10

1 reference

2 December 2017

language of work or name

1 reference

1 April 2003

1 reference

Journal of Clinical Virology

2 December 2017

published in

1 reference

2 December 2017

volume

26

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

277-89; discussion 291-3

1 reference

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

[Bilateral asymmetric herpes zoster in adolescence]

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Disseminated herpes zoster in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Serologic detection of active infections with human herpes viruses (CMV, EBV, HSV, VZV): diagnostic potential of IgA class and IgG subclass-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Assessment of pain in herpes zoster: lessons learned from antiviral trials

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Herpes zoster: a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Prolonged Herpes-Zoster Infection Associated with Immunosuppressive Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Epidemiology of shingles.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Clinical practice. Herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

[Zoster. The manifestation forms in the skin, complications and therapy]

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Oral acyclovir for herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Postherpetic neuralgia--pathogenesis, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Infection with varicella-zoster virus after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

[Zoster and the nervous system]

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Comparative biology of latent varicella-zoster virus and herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

A prognostic score for postherpetic neuralgia in ambulatory patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Population-based study of herpes zoster and its sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Varicella-zoster infection in adult cancer patients. A population study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Clinical uses of cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Hyperkeratotic varicella zoster virus infection in an HIV-infected patient. Successful treatment of persistent lesions with cryosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Herpes zoster, immunological deterioration and disease progression in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Herpes zoster in seven disparate dermatomes (zoster multiplex): report of a case and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

[Herpes zoster: a herpes non-simplex disease]

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900005-2

7 January 2021

10.1016/S1386-6532(03)00005-2

Identifiers

DOI

1 reference

2 December 2017

1 reference